Nancy Joann Johnson Sells 3,418 Shares of Billiontoone (NASDAQ:BLLN) Stock

Billiontoone, Inc. (NASDAQ:BLLN) insider Nancy Joann Johnson sold 3,418 shares of the firm’s stock in a transaction on Monday, June 8th. The stock was sold at an average price of $99.28, for a total value of $339,339.04. Following the completion of the transaction, the insider owned 32,482 shares of the company’s stock, valued at $3,224,812.96. This trade represents a 9.52% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Nancy Joann Johnson also recently made the following trade(s):

• On Tuesday, June 9th, Nancy Joann Johnson sold 10,582 shares of Billiontoone stock. The stock was sold at an average price of $100.47, for a total value of $1,063,173.54.

Billiontoone Stock Down 3.1%

BLLN stock traded down $3.13 during midday trading on Wednesday, reaching $99.26. The stock had a trading volume of 1,040,614 shares, compared to its average volume of 694,048. The company has a debt-to-equity ratio of 0.18, a quick ratio of 10.58 and a current ratio of 10.92. The firm has a fifty day simple moving average of $87.26 and a two-hundred day simple moving average of $88.18. Billiontoone, Inc. has a 52-week low of $61.96 and a 52-week high of $138.70.

Billiontoone (NASDAQ:BLLN) last issued its earnings results on Wednesday, May 6th. The company reported $0.34 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.01 by $0.33. The firm had revenue of $108.39 million during the quarter, compared to analysts’ expectations of $95.81 million. The business’s revenue was up 83.8% on a year-over-year basis. During the same quarter last year, the business earned ($0.39) EPS. On average, research analysts forecast that Billiontoone, Inc. will post 0.93 earnings per share for the current year.

Hedge Funds Weigh In On Billiontoone

A number of institutional investors have recently modified their holdings of the stock. Adams Street Partners LLC purchased a new position in shares of Billiontoone in the 4th quarter valued at about $140,063,000. Baillie Gifford & Co. purchased a new position in shares of Billiontoone in the 4th quarter valued at about $103,786,000. Price T Rowe Associates Inc. MD purchased a new position in shares of Billiontoone in the 4th quarter valued at about $39,717,000. JPMorgan Chase & Co. purchased a new position in shares of Billiontoone in the 4th quarter valued at about $32,078,000. Finally, Wasatch Advisors LP purchased a new position in shares of Billiontoone in the 1st quarter valued at about $29,179,000.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the company. JPMorgan Chase & Co. raised their target price on Billiontoone from $120.00 to $125.00 and gave the stock an “overweight” rating in a research note on Thursday, May 7th. Wall Street Zen upgraded Billiontoone from a “hold” rating to a “buy” rating in a research note on Saturday, March 7th. Guggenheim raised their target price on Billiontoone from $100.00 to $120.00 and gave the stock a “buy” rating in a research note on Wednesday, May 13th. BTIG Research reduced their price objective on Billiontoone from $140.00 to $130.00 and set a “buy” rating for the company in a research note on Thursday, May 7th. Finally, Wells Fargo & Company reduced their price objective on Billiontoone from $110.00 to $90.00 and set an “equal weight” rating for the company in a research note on Thursday, March 5th. Six investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $125.29.

Billiontoone Company Profile

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.